John Wagstaff - Concepedia

Author

John Wagstaff

Also Known As

J D Wagstaff, J Wagstaff, J. WAGSTAFF, J. Wagstaff, JOHN WAGSTAFF, Jan A. Wagstaff, Jayne Wagstaff, John D Wagstaff, John D. Wagstaff, John Wagstaff

321

Publications

43K

Citations

H-Index

187

Concepts

All Affiliations

Swansea University University of Amsterdam Memorial Sloan Kettering Cancer Center Bristol-Myers Squibb (United States)The Christie Hospital

About

John Wagstaff is an author at Swansea University specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	42	99	9.3K
2	Health Sciences	20	25	1.2K
3	Public Health	2	2	145
4	Arts	1	1	30
5	Natural Sciences	1	1	38

John Wagstaff

154

Publications

41.1K

Citations

H-Index

Page 1

	Year	Citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2015	8K
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert J. Motzer, Bernard Escudier, Saby George, New England Journal of Medicine	2015	5.8K
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2017	5.3K
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2019	3.6K
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial Cora N. Sternberg, Ian D. Davis, Jozef Mardiak, Journal of Clinical Oncology UrologyGenitourinary CancerKidney ResearchMedicineLocally Advanced	2010	2.5K
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Nicholas D. James, Matthew R. Sydes, Noel W. Clarke, The Lancet	2015	1.9K
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy Nicholas D. James, Johann S. de Bono, Melissa Spears, New England Journal of Medicine	2017	1.7K
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial F. Stephen Hodi, Vanna Chiarion‐Sileni, René González, The Lancet Oncology MedicineMelanomaClinical TrialsImmune Checkpoint InhibitorDermatology	2018	1.4K
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Zurich Open Repository and Archive (University of Zurich)	2022	557
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial Alison Birtle, Mark Johnson, John Chester, The Lancet	2020	504

Page 1